Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.940.389 €): TRAIN-HEART Hor 26.04.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
TRAIN-HEART
TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Accelero Bioanalytics GmbH | ? |
| Humanitas Mirasole S.p.A. | 522.999 € |
| King's College London | 606.345 € |
| Medizinische Hochschule Hannover | 252.788 € |
| Miltenyi Biotec GmbH | 252.788 € |
| Mirabilis Therapeutics B.V. | 265.620 € |
| Technische Universitaet Muenchen | 505.577 € |
| Universidade do Porto | 475.440 € |
| Universitaetsklinikum Hamburg-Eppendorf | 252.788 € |
| Universiteit Maastricht | 531.240 € |
| Universite Lyon 1 Claude Bernard | 274.802 € |
Quelle: https://cordis.europa.eu/project/id/813716
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Accelero Bioanalytics GmbH, Berlin.